Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
Open Access
- 15 March 2007
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 18 (6), 1085-1089
- https://doi.org/10.1093/annonc/mdm073
Abstract
Background: Secondary central nervous system (CNS) involvement by aggressive lymphoma is a well-known and dreadful clinical complication. The incidence and risk factors for CNS manifestation were studied in a large cohort of elderly (>60 years) patients with aggressive lymphoma. Patients and methods: In all, 444 previously untreated patients were randomized to receive 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) (doxorubicin substituted by mitoxantrone) chemotherapy with or without filgrastim. Prophylactic intrathecal methotrexate was given to patients with lymphoma involvement of bone marrow, testis and CNS near sites. Results: In all 29 of 444 (6.5%) developed CNS disease after a median observation time of 115 months. CNS was the only site of progression/relapse in 13 patients while part of a systemic disease manifestation in 16 patients. In univariate risk factor analysis, CNS occurrence was associated with extranodal involvement of testis (P = 0.002), advanced clinical stage (P = 0.005) and increased age-adjusted International Prognostic Index score (aaIPI; P = 0.035). In multivariate analysis, initial involvement of testis remained significant and clinical stage was of borderline significance. The median survival time was 2 months after presentation of CNS disease. Conclusion: A significant proportion of elderly patients with advanced aggressive lymphoma will develop CNS disease. CNS occurrence is related to testis involvement, advanced clinical stage and high aaIPI and the prognosis is dismal.Keywords
This publication has 20 references indexed in Scilit:
- Central nervous system chemoprophylaxis in non‐Hodgkin lymphoma: current practice in the UKBritish Journal of Haematology, 2005
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLBlood, 2004
- CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trialBlood, 2003
- Central nervous system involvement following diagnosis ofnon-Hodgkin’s lymphoma: a risk modelAnnals of Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysisEuropean Journal Of Cancer, 2000
- For which patients with aggressive non-Hodgkin’s lymphoma is prophylaxis for central nervous system disease mandatory?Annals Of Oncology, 1998
- Central Nervous System Involvement in Patients with Diffuse Aggressive Non-Hodgkinʼs LymphomaAmerican Journal of Clinical Oncology, 1991
- The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1988
- Meningeal involvement in non‐Hodgkin's lymphoma: Symptoms, incidence, risk factors and treatmentScandinavian Journal of Haematology, 1985